ECSP066318A - Composición para la liberación de una base debil por un periodo extendido de tiempo - Google Patents
Composición para la liberación de una base debil por un periodo extendido de tiempoInfo
- Publication number
- ECSP066318A ECSP066318A EC2006006318A ECSP066318A ECSP066318A EC SP066318 A ECSP066318 A EC SP066318A EC 2006006318 A EC2006006318 A EC 2006006318A EC SP066318 A ECSP066318 A EC SP066318A EC SP066318 A ECSP066318 A EC SP066318A
- Authority
- EC
- Ecuador
- Prior art keywords
- composition
- release
- dosage form
- weak base
- time
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Una forma de dosificación oral una primera composición y una segunda composición, y cada composición comprende una base débil farmacéuticamente aceptable, especialmente Compuesto A o una sal o solvato farmacéuticamente aceptable del mismo ("el fármaco") y un vehículo farmacéuticamente aceptable para el mismo, en donde la primera y segunda composiciones están dispuestas para liberar fármaco a diferentes velocidades de liberación tras la administración, de forma que la velocidad de liberación del fármaco a partir de la forma de dosificación es sustancialmente independiente del pH; un procedimiento para preparar esta forma de dosificación y el uso de esta forma de dosificación en medicina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49338803P | 2003-08-07 | 2003-08-07 | |
PCT/EP2004/008843 WO2005013935A2 (en) | 2003-08-07 | 2004-08-06 | Composition for releasing a weak base for an extended period of time |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP066318A true ECSP066318A (es) | 2006-07-28 |
Family
ID=34135242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2006006318A ECSP066318A (es) | 2003-08-07 | 2006-01-25 | Composición para la liberación de una base debil por un periodo extendido de tiempo |
Country Status (25)
Country | Link |
---|---|
US (1) | US20070134326A1 (es) |
EP (1) | EP1660049A2 (es) |
JP (1) | JP2007501773A (es) |
KR (1) | KR20060113650A (es) |
CN (2) | CN1832729A (es) |
AP (1) | AP2006003488A0 (es) |
AR (1) | AR045330A1 (es) |
AU (1) | AU2004262926B2 (es) |
BR (1) | BRPI0413374A (es) |
CA (1) | CA2534546A1 (es) |
EA (2) | EA011508B1 (es) |
EC (1) | ECSP066318A (es) |
IL (1) | IL173176A0 (es) |
IS (1) | IS8336A (es) |
MA (1) | MA27980A1 (es) |
MX (1) | MXPA06001407A (es) |
NO (1) | NO20061018L (es) |
NZ (1) | NZ544696A (es) |
OA (1) | OA13230A (es) |
PE (1) | PE20050335A1 (es) |
SG (1) | SG145717A1 (es) |
TW (1) | TW200517127A (es) |
UY (1) | UY28457A1 (es) |
WO (1) | WO2005013935A2 (es) |
ZA (1) | ZA200600521B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0203296D0 (en) * | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
US8637512B2 (en) * | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
EP1686967A4 (en) * | 2003-11-25 | 2012-08-08 | Smithkline Beecham Cork Ltd | CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES |
GB0502475D0 (en) * | 2005-02-07 | 2005-03-16 | Sb Pharmco Inc | Novel compositions |
GB0502479D0 (en) * | 2005-02-07 | 2005-03-16 | Sb Pharmco Inc | Novel compositions |
US20100323016A1 (en) * | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
US20100323015A1 (en) * | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
KR101697800B1 (ko) | 2009-02-13 | 2017-01-18 | 로마크 레버러토리즈, 엘.씨. | 니타족사니드의 서방성 제약 제형 |
KR20120118012A (ko) | 2010-01-20 | 2012-10-25 | 글락소 그룹 리미티드 | 신규의 레티가빈 조성물 |
CN103948557A (zh) * | 2014-04-08 | 2014-07-30 | 闻晓光 | 一种新型控释片 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8820353D0 (en) * | 1988-08-26 | 1988-09-28 | Staniforth J N | Controlled release tablet |
FR2655266B1 (fr) * | 1989-12-05 | 1992-04-03 | Smith Kline French Lab | Compositions pharmaceutiques a base de cimetidine. |
IT1264517B1 (it) * | 1993-05-31 | 1996-09-24 | Ekita Investments Nv | Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati |
HU213407B (en) * | 1993-12-09 | 1997-06-30 | Egyt Gyogyszervegyeszeti Gyar | Process for producing tablet with diffusive-osmotic release |
US5407687A (en) * | 1994-02-22 | 1995-04-18 | Glaxo Inc. | Ranitidine solid dosage form |
US5952509A (en) * | 1996-06-27 | 1999-09-14 | Takeda Chemical Industries, Ltd. | Production of benzaldehyde compounds |
GB9619757D0 (en) * | 1996-09-21 | 1996-11-06 | Knoll Ag | Chemical process |
US20010049380A1 (en) * | 1997-06-18 | 2001-12-06 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and sulphonylurea |
US20020004515A1 (en) * | 1997-06-18 | 2002-01-10 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and metformin |
US20020006939A1 (en) * | 1997-10-13 | 2002-01-17 | Smithkline Beecham P.L.C. | Use of thiazolidinediones for the treatment of hyperglycaemia |
US6099859A (en) * | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
US20040102486A1 (en) * | 1998-11-12 | 2004-05-27 | Smithkline Beecham Corporation | Novel method of treatment |
US20030153607A1 (en) * | 1998-11-12 | 2003-08-14 | Smithkline Beecham P.L.C. | Novel composition and use |
EA007610B1 (ru) * | 1998-11-12 | 2006-12-29 | Смитклайн Бичам Плс | Таблетка с энтеропокрытием, обеспечивающая отсроченное высвобождение |
US20040081697A1 (en) * | 1998-11-12 | 2004-04-29 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
ES2290130T3 (es) * | 2000-05-01 | 2008-02-16 | Aeropharm Technology, Llc | Formulacion de nucleo. |
GB0117618D0 (en) * | 2001-07-19 | 2001-09-12 | Phoqus Ltd | Pharmaceutical dosage form |
GB0127805D0 (en) * | 2001-11-20 | 2002-01-09 | Smithkline Beecham Plc | Pharmaceutical composition |
PE20030800A1 (es) * | 2002-02-12 | 2003-10-31 | Glaxo Group Ltd | Forma de dosificacion oral de liberacion controlada |
GB0203296D0 (en) * | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
-
2004
- 2004-08-05 UY UY28457A patent/UY28457A1/es not_active Application Discontinuation
- 2004-08-05 TW TW093123415A patent/TW200517127A/zh unknown
- 2004-08-05 AR ARP040102794A patent/AR045330A1/es not_active Application Discontinuation
- 2004-08-05 PE PE2004000757A patent/PE20050335A1/es not_active Application Discontinuation
- 2004-08-06 MX MXPA06001407A patent/MXPA06001407A/es unknown
- 2004-08-06 OA OA1200600040A patent/OA13230A/en unknown
- 2004-08-06 SG SG200805824-0A patent/SG145717A1/en unknown
- 2004-08-06 KR KR1020067002663A patent/KR20060113650A/ko not_active Application Discontinuation
- 2004-08-06 CN CNA2004800226534A patent/CN1832729A/zh active Pending
- 2004-08-06 AP AP2006003488A patent/AP2006003488A0/xx unknown
- 2004-08-06 NZ NZ544696A patent/NZ544696A/en unknown
- 2004-08-06 EA EA200600377A patent/EA011508B1/ru not_active IP Right Cessation
- 2004-08-06 CN CNA2008100088784A patent/CN101239047A/zh active Pending
- 2004-08-06 EP EP04763874A patent/EP1660049A2/en not_active Withdrawn
- 2004-08-06 AU AU2004262926A patent/AU2004262926B2/en not_active Ceased
- 2004-08-06 EA EA200701409A patent/EA200701409A1/ru unknown
- 2004-08-06 JP JP2006522328A patent/JP2007501773A/ja not_active Withdrawn
- 2004-08-06 CA CA002534546A patent/CA2534546A1/en not_active Abandoned
- 2004-08-06 WO PCT/EP2004/008843 patent/WO2005013935A2/en active Application Filing
- 2004-08-06 BR BRPI0413374-9A patent/BRPI0413374A/pt not_active Application Discontinuation
- 2004-08-06 US US10/567,146 patent/US20070134326A1/en not_active Abandoned
-
2006
- 2006-01-16 IL IL173176A patent/IL173176A0/en unknown
- 2006-01-18 ZA ZA200600521A patent/ZA200600521B/en unknown
- 2006-01-25 EC EC2006006318A patent/ECSP066318A/es unknown
- 2006-02-07 MA MA28777A patent/MA27980A1/fr unknown
- 2006-03-01 NO NO20061018A patent/NO20061018L/no not_active Application Discontinuation
- 2006-03-02 IS IS8336A patent/IS8336A/is unknown
Also Published As
Publication number | Publication date |
---|---|
MA27980A1 (fr) | 2006-07-03 |
CA2534546A1 (en) | 2005-02-17 |
US20070134326A1 (en) | 2007-06-14 |
NZ544696A (en) | 2009-03-31 |
AP2006003488A0 (en) | 2006-02-28 |
EA200701409A1 (ru) | 2007-10-26 |
JP2007501773A (ja) | 2007-02-01 |
KR20060113650A (ko) | 2006-11-02 |
EA200600377A1 (ru) | 2006-08-25 |
WO2005013935A3 (en) | 2005-07-14 |
AU2004262926B2 (en) | 2009-11-19 |
OA13230A (en) | 2006-12-13 |
CN101239047A (zh) | 2008-08-13 |
WO2005013935A2 (en) | 2005-02-17 |
UY28457A1 (es) | 2005-03-31 |
PE20050335A1 (es) | 2005-06-01 |
ZA200600521B (en) | 2007-01-31 |
CN1832729A (zh) | 2006-09-13 |
IL173176A0 (en) | 2006-06-11 |
NO20061018L (no) | 2006-03-01 |
TW200517127A (en) | 2005-06-01 |
SG145717A1 (en) | 2008-09-29 |
IS8336A (is) | 2006-03-02 |
EP1660049A2 (en) | 2006-05-31 |
MXPA06001407A (es) | 2006-05-15 |
EA011508B1 (ru) | 2009-04-28 |
AR045330A1 (es) | 2005-10-26 |
BRPI0413374A (pt) | 2006-10-17 |
AU2004262926A1 (en) | 2005-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP066318A (es) | Composición para la liberación de una base debil por un periodo extendido de tiempo | |
BRPI0015567B8 (pt) | composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica | |
UY27533A1 (es) | Composiciones farmacéuticas que contienen oxibutinina | |
NO993520L (no) | Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon | |
EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
UY27908A1 (es) | Formulaciones y formas de dosificación para la administración controlada de topiramato | |
NO20063429L (no) | Brusende oral opiat doseringsform | |
BR0112311A (pt) | Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso | |
TW200500098A (en) | Methods and dosage forms for increasing solubility of drug compositions for controlled delivery | |
EA200301165A1 (ru) | Лекарственное средство на основе оксикодона | |
CL2009001682A1 (es) | Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00). | |
ATE466008T1 (de) | P-glycoprotein-inhibitor, verfahren zu dessen herstellung und pharmazeutische zusammensetzung, die diesen enthält | |
DE60336225D1 (de) | Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend | |
DE50203456D1 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
ATE442158T1 (de) | Oral verabreichte pharmazeutische zusammensetzungen mit einem abgabemittel in mikronisierter form | |
TR200601092T1 (tr) | İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar. | |
UY26176A1 (es) | Formas polimorfas de un citrato de azobiciclo (2,2,2) octan- 3-amina y sus composiciones farmacéuticas. | |
ATE302010T1 (de) | Pharmazeutische zusammensetzung, enthaltend desoxypeganin zur behandlung des alkoholismus | |
AR031104A1 (es) | Composicion farmaceutica que comprende un carboxialquileter y un agente antihipertensivo, primera composicion para su uso con una segunda composicion que comprenden un agente antihipertensivo y un carboxialquileter respectivamente, equipo que comprende un carboxialquileter y un agente antihipertensi | |
UY26177A1 (es) | Polimorfos de un citrato de azobiciclo (2.2.2) oct-3- ilamina cristalino y sus composiciones farmacéuticas. | |
TH78324B (th) | องค์ประกอบชนิดใหม่ | |
BR0311209A (pt) | Método de produção de unidades de dosagem farmacêuticas para administração oral, uso de etonogestrel, e, tablete | |
TH78324A (th) | องค์ประกอบชนิดใหม่ | |
PE20011042A1 (es) | Uso de glutamina para la prevencion de diarrea de inicio tardio inducida por irinotecan | |
RU2007120495A (ru) | Анорексигенное и регулирующее массу тела лекарственное средство |